Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection

Eye

Volumn 22, Issue 7, 2008, Pages 895-899

  Chu, Y K ^a   Chung, E J ^b   Kwon, O W ^b   Lee, J H ^c   Koh, H J ^b  

^a Siloan Eye Hospital   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Konyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG MEGADOSE; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; MEDICAL ASSESSMENT; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA VEIN OCCLUSION; SCLEROSIS; STATISTICAL ANALYSIS;

EID: 48049115492     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702802     Document Type: Article

References (34)

1. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131: 468-471.
2. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-427.
3. Martidis A, Duker JS, Greenberg PB, Rogers AH Pulliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.
4. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM. Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmol 2001; 108:765-772.
5. Young S, Larkin G, Branley M, Lightman, S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001; 29: 2-6.
6. Greenberg PB, Martidis A, Rogers AH, Duker JS, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein, occlusion. Br J Ophthalmol 2002; 86: 248.
7. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL. Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Opthalmic Surg Laser Imaging 2005; 36: 30-36.
8. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated irtraocular pressure. Aust N Z J Ophthalmol 1999; 27: 431-432.
9. Gillies MC, Kuzniarz M, Craig J, Ball M, Luo W, Simpson JM et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005; 112: 139-143
10. Mohan R, Muralidharan AR. Steroid induced glaucoma and cataract. Indian J Opthalmol 1989; 37: 13-16.
11. Massin P, Audren F, Haouchine B. Erginay A. Bergmann JF, Benosman R et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-2244.
12. Krepler K, Wagner J, Sacu S, Wedrich A. The effect of intravitreal triamcinolone on diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2005; 243: 478-481.
13. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters III GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110: 681-686.
14. Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomized eye. Br J Ophthalomol 2006; 90: 705-708.
15. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002; 86 1450-1457.
16. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in aqueous humor. Br J Ophthalmol 2002; 86: 1066.
17. Jonas JB, Degenring R, Kamppeter B, Kreissig I, Akkoyun I. Duration of the effect of intravitreal triamcinolone acetonide as treatment of diffuse diabetic macular edema. Am J Ophthalmol 2004; 138: 158-160.
18. Chylack Jr LT, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL et al. The lens opacities classification system (LOCS) III: longitudinal study of the Cataract Study Group. Arch Ophthalmol 1993; 111: 831-836.
19. Kang BS, Chung EY, Yun YP, Lee MK, Lee YR, Lee KS et al. inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. Biol Pharm Bull 2001; 24: 701-703.
20. Umdand SF, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW et al The inhibitory effects of topically, active gucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4 + T cells. J Allergy Clin Immunol 1997; 100: 511-519.
21. Floman N, Zor U. Mechanism of steroid action in ocular inflammation: inhibition of prostaglandin production. Invest Ophthalmol 1977; 16: 69-73.
22. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol 2001; 425: 109-116.
23. Sze PY, lqbal Z. Glucocorticoid action on depolarization-dependent calcium influx in brair, synaptosomes. Neuroendocrinology 1994; 59: 457-465.
24. Scholes; GN, O'Brien WJ, Abrams G, Kubieck MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol 1985; 103: 1567-1569.
25. Schindler RH, Chandler DB, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 1982; 93 415-417.
26. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan Jr E et al Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-1159.
27. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al Safety of an intranvitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-3340.
28. Helm CJ. Holland GN. The effects of posterior subtenon injection of triamcinolone. Am J Ophthalmol 1995; 120: 55-64.
29. Cha JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA et al Exudative macular degeneration and intravitreal trianicinollone: 18 month follow-up. Aust N Z J Opthalmol 1998; 26: 277-281.
30. Chieh JJ, Roth DB, Liu M, Bellmont J, Nelson M, Reqillo C et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina 2005; 25: 828-834.
31. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macullar laser grid photocoagoplation for the treatment of cystoid macular edema. Am J Ophthalmol 2005; 140: 695-702.
32. Jonas JB, Kreissing I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003; 121: 57-61.
33. Lam DS, Chan CK, Mohamed S, Lai TY, Li KK, Li PS et al. A prospective randomized trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthamol 2007; 91: 199-203.
34. Sasaki K. Cataract epidemiology performed with Scheimpflug documentation. Ophthalmic Res 1999; 31: 75-85.